California Public Employees Retirement System Acquires 5,200 Shares of Corcept Therapeutics Incorporated (CORT)

California Public Employees Retirement System grew its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 3.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,200 shares of the biotechnology company’s stock after acquiring an additional 5,200 shares during the period. California Public Employees Retirement System owned about 0.13% of Corcept Therapeutics worth $1,749,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Bank of Montreal Can grew its position in shares of Corcept Therapeutics by 111.2% during the 2nd quarter. Bank of Montreal Can now owns 34,931 shares of the biotechnology company’s stock valued at $413,000 after acquiring an additional 18,389 shares during the period. Birchview Capital LP grew its position in shares of Corcept Therapeutics by 58.3% during the 2nd quarter. Birchview Capital LP now owns 95,000 shares of the biotechnology company’s stock valued at $1,121,000 after acquiring an additional 35,000 shares during the period. Rhumbline Advisers grew its position in shares of Corcept Therapeutics by 21.5% during the 2nd quarter. Rhumbline Advisers now owns 87,672 shares of the biotechnology company’s stock valued at $1,035,000 after acquiring an additional 15,494 shares during the period. Prudential Financial Inc. grew its position in shares of Corcept Therapeutics by 3,409.5% during the 2nd quarter. Prudential Financial Inc. now owns 633,223 shares of the biotechnology company’s stock valued at $7,472,000 after acquiring an additional 615,180 shares during the period. Finally, Timpani Capital Management LLC bought a new stake in shares of Corcept Therapeutics during the 2nd quarter valued at $1,484,000. 62.22% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/05/california-public-employees-retirement-system-acquires-5200-shares-of-corcept-therapeutics-incorporated-cort.html.

Corcept Therapeutics Incorporated (CORT) opened at $17.32 on Friday. The firm has a market cap of $1,964.05, a price-to-earnings ratio of 59.72 and a beta of 2.04. Corcept Therapeutics Incorporated has a 1-year low of $6.70 and a 1-year high of $20.77.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.02). The firm had revenue of $42.70 million during the quarter, compared to the consensus estimate of $41.64 million. Corcept Therapeutics had a return on equity of 67.59% and a net margin of 27.28%. The company’s quarterly revenue was up 96.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.02 EPS. equities analysts predict that Corcept Therapeutics Incorporated will post 0.44 earnings per share for the current year.

A number of brokerages have recently issued reports on CORT. Zacks Investment Research downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Piper Jaffray Companies set a $18.00 price objective on shares of Corcept Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 24th. BidaskClub downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 4th. Stifel Nicolaus began coverage on shares of Corcept Therapeutics in a research report on Thursday, August 31st. They set a “buy” rating and a $20.00 price objective for the company. Finally, Ladenburg Thalmann Financial Services set a $20.00 price objective on shares of Corcept Therapeutics and gave the company a “buy” rating in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Corcept Therapeutics currently has an average rating of “Buy” and a consensus target price of $18.20.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

What are top analysts saying about Corcept Therapeutics Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corcept Therapeutics Incorporated and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit